THU0499 The effect of concomitant type of vitamin d, biological dmards and disease activity for therapeutic effect of denosumab in osteoporosis patients with rheumatoid arthritis
BackgroundOsteoporosis is one of the major comorbidity in patients with rheumatoid arthritis (RA). There are a lot of evidence that denosumab increase bone mineral density (BMD) in patients with osteoporosis. However, there are few reports investigated the influence of denosumab in patients with RA....
Saved in:
Published in | Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 456 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.06.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | BackgroundOsteoporosis is one of the major comorbidity in patients with rheumatoid arthritis (RA). There are a lot of evidence that denosumab increase bone mineral density (BMD) in patients with osteoporosis. However, there are few reports investigated the influence of denosumab in patients with RA.ObjectivesWe evaluated the BMD change in patients with RA treated denosumab and assessed the effect of verious factors, such as the type of vitamin D, biological disease-modifying anti-rheumatic drugs (bDMARDs) use, and disease activity.MethodsThis study included 100 RA patients (96 female, mean age 69.9±9.3 years) treated with denosumab. BMD at the lumbar spine and proximal femoral were evaluated by dual energy X-ray absorptiometry (DXA) at baseline and 1 year after treatment. We evaluated the influence of the type of vitamin D, bDMARDs and disease activity for BMD change.ResultsIn all patients, BMD at the lumbar spine, proximal femoral and femoral neck were significantly increased in one years (6.2%: p<0.01, 4.0%: p<0.01, 2.2%: p=0.04, respectively). There were no significant differences in improvement ratio of BMD between 10 patients taking active form vitamin D and 71 patients taking native form vitamin D (7.7 vs 4.4%: p=0.55, 4.3 vs 4.0%: p=0.83, 1.4 vs 4.2%: p=0.52), between 30 patients treated with bDMARDs and 57 patients treated without bDMARDs (6.4 vs 6.2%: p=0.3, 2.7 vs 4.5%: p=0.95, 1.1 vs 2.5%: p=0.2), between 61 patients in remission or low disease activity and 26 patients in moderate or high disease activity (7.2 vs 4.0%: p=0.25, 3.3 vs 5.0%: p=0.87, 1.6 vs 3.8%: p=0.98) (figure 1).Figure 1BMD changeConclusionsDenosumab improved BMD in patients with RA independently regardless of the type of vitamin D, bDMARDs use, disease activity.Disclosure of InterestNone declared |
---|---|
ISSN: | 0003-4967 1468-2060 |
DOI: | 10.1136/annrheumdis-2018-eular.3321 |